Q-State Biosciences (“Q-State”), a discovery-stage therapeutics and technology company advancing programs for the treatment of epilepsy, pain, and other disorders of the central nervous system, presented new data today at the 2021 Neuroimmunology Drug Development (NIDD) Summit
April 28, 2021
· 1 min read